| Patent | Date |
|---|
Method for solubilizing poorly water-soluble cosmetic agents
Grant 11,207,256 - Saar , et al. December 28, 2 | 2021-12-28 |
Methhod for producing a crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione
Grant 11,203,575 - Martin , et al. December 21, 2 | 2021-12-21 |
Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione
Grant 11,111,218 - Martin , et al. September 7, 2 | 2021-09-07 |
Method For Solubilizing Poorly Water-soluble Dietary Supplements And Pharmaceutically Active Agents
App 20210205345 - Saar; Ingo ; et al. | 2021-07-08 |
Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of chronic progressive multiple sclerosis
Grant 11,007,192 - Brysch , et al. May 18, 2 | 2021-05-18 |
Method For Solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione
App 20210061771 - Saar; Ingo ; et al. | 2021-03-04 |
Krill Oil For Solubilizing Poorly Water-soluble Dietary Supplements And Pharmaceutically Active Agents
App 20200397905 - Saar; Ingo ; et al. | 2020-12-24 |
Method For Producing A Crystalline Form Of 5-amino-2,3-dihydrophthalazine-1,4-dione
App 20200369623 - MARTIN; Thomas ; et al. | 2020-11-26 |
Crystalline Form Of 5-amino-2, 3-dihydrophthalazine-1, 4-dione
App 20200369624 - MARTIN; Thomas ; et al. | 2020-11-26 |
Method For Solubilizing Poorly Water-soluble Cosmetic Agents
App 20200170915 - Saar; Ingo ; et al. | 2020-06-04 |
Dispensing Cap Containing A Solubilisate Of A Pharmaceutically Active Agent Or Dietary Supplement
App 20200113824 - Brysch; Ekkehard ; et al. | 2020-04-16 |
Agents for the treatment of retroviral infectious diseases
Grant 10,588,896 - Schubert , et al. | 2020-03-17 |
Use Of 5-amino-2,3-dihydro-1,4-phthalazinedione In The Treatment Of Chronic Progressive Multiple Sclerosis
App 20190358227 - Brysch; Wolfgang ; et al. | 2019-11-28 |
Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said form
Grant 10,258,620 - Martin , et al. | 2019-04-16 |
Beverage Preparation Capsule For Delivery Of A Solubilisate
App 20190084757 - Brysch; Ekkehard ; et al. | 2019-03-21 |
Crystalline Form Of 5-amino-2,3-dihydrophthalazine-1,4-dione Sodium Salt, Pharmaceutical Preparations Containing The Same And Method For The Production Of Said Form
App 20170368063 - Martin; Thomas ; et al. | 2017-12-28 |
Agents For The Treatment Of Retroviral Infectious Diseases
App 20170202814 - Schubert; Ulrich ; et al. | 2017-07-20 |
Crystalline forms for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said forms
Grant 9,079,863 - Breu , et al. July 14, 2 | 2015-07-14 |
Crystalline forms for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said forms
App 20140303169 - BREU; Josef ; et al. | 2014-10-09 |
Crystalline forms for 5-amino-2, 3-dihydrophthalazine-1, 4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said forms
Grant 8,772,294 - Breu , et al. July 8, 2 | 2014-07-08 |
Method for stimulating the immune system
Grant 8,629,117 - Schlingensiepen , et al. January 14, 2 | 2014-01-14 |
Crystalline Forms For 5-amino-2, 3-dihydrophthalazine-1, 4-dione Sodium Salt, Pharmaceutical Preparations Containing The Same And Method For The Production Of Said Forms
App 20120329801 - Breu; Josef ; et al. | 2012-12-27 |
Antisense-oligonucleotides for the treatment of immuno-suppressive effects of transforming growth factor-.beta. (TGF-.beta.)
Grant 7,667,027 - Schlingensiepen , et al. February 23, 2 | 2010-02-23 |
Antisense oligonucleotide preparation method
Grant 7,563,778 - Schlingensiepen , et al. July 21, 2 | 2009-07-21 |
Antisense-oligonucleotides for the treatment of immuno-suppressive effects of transforming growth factor-beta (TGF-beta)
App 20080214483 - Schlingensiepen; Georg-Ferdinand ; et al. | 2008-09-04 |
Method for stimulating the immune system
App 20080124301 - Schlingensiepen; Karl-Hermann ; et al. | 2008-05-29 |
Pharmaceutical composition comprising antisense-nucleic acid for prevention and/or treatment of neuronal injury, degeneration and cell death and for the treatment of neoplasms
Grant 7,326,783 - Schlingensiepen , et al. February 5, 2 | 2008-02-05 |
Method for reversing the immunosuppressive effects of the melanoma inhibitory activity "mia"
App 20060252716 - Schlingensiepen; Karl-Hermann ; et al. | 2006-11-09 |
Antisense oligonucleotide preparation method
Grant 6,972,171 - Schlingensiepen , et al. December 6, 2 | 2005-12-06 |
Antisense oligonucleotide preparation method
App 20050130927 - Schlingensiepen, Karl-Hermann ; et al. | 2005-06-16 |
Antisense-oligonucleotides for the treatment of immuno-suppressive effects of transforming growth factor-beta (TGF-beta)
App 20030040499 - Sclingensiepen, Georg-Fredinand ; et al. | 2003-02-27 |
Antisense-oligonucleotides for transforming growth factor-.beta. (TGF-.beta.)
Grant 6,455,689 - Schlingensiepen , et al. September 24, 2 | 2002-09-24 |
Antisense nucleic acids for the prevention and treatment of disorders in which expression of c-erbB plays a role
Grant 6,365,345 - Brysch , et al. April 2, 2 | 2002-04-02 |
Pharmaceutical Composition Comprising Antisense-nucleic Acid For Prevention And/or Treatment Of Neuronal Injury, Degeneration And Cell Death And For The Treatment Of Neoplasms
App 20020037866 - SCHLINGENSIEPEN, GEORG-F ; et al. | 2002-03-28 |
| 